![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Eden Research Plc | LSE:EDEN | London | Ordinary Share | GB0001646941 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.35 | 4.20 | 4.50 | 4.35 | 4.35 | 4.35 | 0.00 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 1.83M | -2.24M | -0.0042 | -10.36 | 23.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/5/2023 13:31 | Master Investor Show 2023 - Sean Smith - Eden Research plc While Atul watches patiently. | ![]() supersonico | |
12/5/2023 11:08 | Least successful pump I've ever seen..... I do not think the RNS should have any speculative figures - that info should be in the marketing material. | ![]() timbo_slice | |
12/5/2023 09:56 | Investing , Yes these maybe conservative numbers but it's unusual for Smith to be so detailed with the potential sales figures. (3% for both Mev and Ced ..two different products.. yet both achieving exact same market penetration??) Yes he has gotten burnt by guesstimating regulators approval times but historically has always referred to market size and never to Eden's own anticipated 'peak' sales opportunity. Given that this is not my first rodeo I'm guessing (as always) that this is a market subduing tactic in preparation for a Corteva or other whale strategic investment. I don't expect Smith and Co to change their spots so when they make uncharacteristic commentary my attention is guaranteed. AWGATWT. | ![]() supersonico | |
12/5/2023 08:56 | I think these will be very conservative numbers, don't you? The Company is unlikely to come out and say they expect to get 25% market share on a brand new product in a brand new geography. I don't know what they anticipate if these numbers are conservative, but I would expect them to be greater than this. Also, given how California is considered about green issues, you would expect much bigger uptake. | ![]() investingisatrickygame | |
12/5/2023 08:51 | ROTFLMAO @ gullible suckers!!!! ;D :D ;D | ![]() neutralpov | |
12/5/2023 07:46 | They are still waiting on Mevalone in california. Should be rubber stamped as grapes already cleared for cedroz. | ![]() babysitter | |
12/5/2023 07:38 | Jonesy, Have to agree.. those numbers look puzzling to me and don't meet my understanding of 'opening up significant revenue opportunities for the company'. Both 94 divided by 2.8 and 189 divided by 5.7 come to 33 ish. Are Eden saying they're optimally anticipating achieving 3% market share? | ![]() supersonico | |
12/5/2023 07:16 | Not a straightforward RNS to understand. Please can someone help me interpret these different numbers in the same release. Does it mean they are targeting a small proportion of the overall market or is it a mistake?"a market potential in the US of approximately EUR94 million for Mevalone and EUR189 million for Cedroz""Potential sales in the US, as a whole, are estimated to be c.2.8m for Mevalone and 5.7m for Cedroz, based on peak sales and a full label of all key target diseases and crops"And also what it means that Eden's application for regulatory approval in California is still in progress,with clearance expected to be received soon.Thanks! | ![]() jonesy100 | |
12/5/2023 07:13 | Regulatory approvals in California and Florida | ![]() supersonico | |
09/5/2023 10:48 | Canary told you world citizens so... EXCESS DEATHS IN THE UK +22% VS 5 YEAR AVERAGE * $PFE They knew in 2018 that MRNA had most of the adverse events we see today were known to be caused by mRNA or at least enough of a correlation that FDA would not allow it on the market. Sadly they found a bunch of others! | ![]() supersonico | |
07/5/2023 22:51 | STFU, you ignorant subsonic moron. You belong in a padded cell. My only regret is I won't be able to see video of you once you're committed. | ![]() neutralpov | |
07/5/2023 11:17 | Is that another one of your legendary Lube 'best guesses'? 'Therefore my best guess at zero pence is June 30th'. 'However I expect Eden to delist and go private before then'. 'If that fails it will be a prepackaged administration which will end up with the biggest shareholders and Corteva owning Eden'. | ![]() supersonico | |
07/5/2023 11:06 | NB Eden have not declared their current cash position. £1m of the money at end December could be gone by now. | ![]() ravenna23 | |
07/5/2023 07:52 | Food for thought for Global Citizen Smith. Eden Research - ESG Strategy p31. 'In agriculture there is an urgent need to move to a safe , equitable and sustainable food system.' James Lindsay at European Parliament - Woke Conference (This is where Tara comes in) 'Writing in the 19 sixties said extremely clearly this writing in 1969 not only did he say capitalism delivers the goods, gives people a good life, makes them wealthy and comfortable and happy. He also said that the working class is no longer going to be the base of the revolution because of these things. In other words, we don't have to be responsible to the working class anymore, which opens up the ability for Marxists who are seeking power to make friends with the corporations, the bosses are no longer the enemy. They're an opportunity because the working class is irrelevant' . | ![]() supersonico | |
06/5/2023 08:38 | And that wipe is YOU. Never mind, you'll have plenty of time to pay closer attention to the irrelevant as you struggle to get out of the jacket where the buttons (and your arms) are all at the back. Tricky, though, hopefully will prove a nice nocturnal plaything for Sammy boy in the cell they will share. Throw the key away, I say.... | ![]() neutralpov | |
05/5/2023 18:02 | Someone is not paying close enough attention . | ![]() supersonico | |
05/5/2023 17:43 | Chair Lykele van der Broek says: ‘2022 was a positive year for Eden with a return to strong sales growth and approval for Eden’s two commercial products, Mevalone and Cedroza, and three active ingredients granted approval in the US. 2023 looks set to provide a number of significant opportunities including further territorial expansion and targeted diseases, increased products sales, and the continued development of other product lines such as our seed treatment and insecticide projects.’ What planet is this man living on. Eden is finished - over quarter of a century and sales remain negligible, losses significant in proportion to sales. Eden is a basket case. It cannot survive much longer. | erinvale1 | |
05/5/2023 13:39 | Says the fella who still can't say Cedroz. ..and deletes total history of Eden commentary.. why would he do that? Not serious or credible Lube | ![]() supersonico | |
05/5/2023 12:55 | Oh come on Investing ..you can't be serious. Surely these three questionable staff-what-staff Lube statements all can't be wrong? 'Therefore my best guess at zero pence is June 30th'. 'However I expect Eden to delist and go private before then'. 'If that fails it will be a prepackaged administration which will end up with the biggest shareholders and Corteva owning Eden'. ravenna23 - 13 Jan 2023 - 13:31:40 - 13657 of 13962 Eden Research - EDEN In order to survive 2023 at the current rate of cash burn, Eden must raise funds before the year end accounts are published. If they fail to do so the new auditor must qualify the accounts on a going concern basis. They can delay accounts until end June but this will earn them another black mark with the regulator. Therefore my best guess at zero pence is June 30th. However I expect Eden to delist and go private before then. If that fails it will be a prepackaged administration which will end up with the biggest shareholders and Corteva owning Eden. Krill are not chill. | ![]() supersonico | |
05/5/2023 12:29 | hxxps://polaris.brig "The Directors have, at the time of approving the financial statements, a reasonable expectation that the Group and Company have adequate resources to continue in operational existence for at least 12 months from the approval of the financial statements. Thus, the financial statements have been prepared on a going concern basis which contemplates the realisation of assets and the settlement of liabilities in the ordinary course of business." BASE CASE scenario "A positive cash balance is forecasted to be maintained in this base scenario throughout the entire forecast period." "The Directors have also considered a downside scenario which includes reductions to revenue derived from existing contracts as well as elimination of revenue from products not yet available for use offset by mitigations around research and development expenditure as well as some reductions in expansionary overheads. Under this scenario, a positive cash balance would be maintained over the forecast period." AT LEAST 12 Months "Consequently, the Directors are confident that the Group and Company will have sufficient funds to continue to meet their liabilities as they fall due for at least 12 months from the date of approval of the financial statements and therefore have prepared the financial statements on a going concern basis." I could go on with endless statements to the positive | ![]() investingisatrickygame |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions